Merck: three new indications for Keytruda in Japan

(CercleFinance.com) - Merck announces that the Japanese Ministry of Health has approved its Keytruda, in combination with chemotherapy, as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for non-small cell lung carcinoma.


It has also been approved in Japan in radically unresectable urothelial carcinoma, in combination with Padcev for first-line treatment, and as monotherapy in patients not eligible for platinum-containing chemotherapy.

The pharmaceutical company specifies that these three new indications are based respectively on the results of the KEYNOTE-671 and KEYNOTE-A39 phase III trials, as well as the KEYNOTE-052 phase II trial.


Copyright (c) 2024 CercleFinance.com. All rights reserved.